Deal Structure Guide
How to Run a Biotech Out-Licensing Process
From positioning to close — the sequence that determines whether you capture full value.
What an out-licensing process is
Out-licensing is the process by which a company grants rights to its intellectual property — a drug candidate, a platform technology, or a diagnostic tool — to a partner who will develop and/or commercialize it in exchange for economic consideration: upfront payments, milestones, and royalties.
Unlike sell-side M&A, where the entire company changes hands, out-licensing involves carving specific rights (by territory, indication, field, or modality) while the licensor retains everything else. The retained optionality is one of the key advantages of licensing over M&A for companies that believe their pipeline has multiple shots on goal.
A well-run out-licensing process is a structured, competitive process that positions the asset for maximum counterparty interest and extracts full economic value through managed competition. An ad hoc process — responding to inbound interest, entering bilateral discussions without competitive tension — consistently produces inferior outcomes. The difference between a structured and unstructured process is not incremental; it is typically 30-60% in upfront economics alone.
The phases of a structured out-licensing process
Phase 1: Positioning (4-8 weeks). Before any counterparty sees the asset, the positioning must be right. This means: a clear value proposition that speaks to what the counterparty is trying to build, not just what the asset does; a competitive frame that defines which comparable transactions set the valuation anchor; a data presentation that addresses the obvious questions before they are asked; and a deal structure framework that defines the licensor's minimum acceptable terms.
Phase 2: Counterparty Mapping and Outreach (2-4 weeks). Identifying the right counterparties is not the same as listing everyone who might be interested. The right counterparties are those with: a strategic need the asset addresses, the financial capacity to execute, the development infrastructure to advance the program, and a track record of honoring deal terms post-signing. Outreach should be calibrated — enough parties to create competition, not so many that confidential data is spread across the industry.
Phase 3: Controlled Diligence (4-8 weeks). Counterparties who sign CDAs receive a structured data package and management presentation. The process is managed so that all parties are on a similar timeline, creating the competitive dynamic that drives economics. Questions are fielded, follow-up data is provided, and the licensor maintains control of the information flow.
Phase 4: Term Sheet Negotiation and Close (6-12 weeks). Non-binding term sheets are solicited on a defined timeline. The licensor evaluates offers across multiple dimensions — not just upfront, but total economics, deal structure, development commitment, and partner quality. Selected parties move to definitive agreements. The process closes when both sides sign.
What the data shows about process outcomes
Process design matters more than most licensors realize. Our database allows us to compare outcomes across different process structures.
Competitive processes — those involving three or more engaged counterparties at the term sheet stage — generate median upfronts approximately 40% higher than bilateral negotiations for otherwise comparable assets. The premium holds across stages and therapeutic areas.
Process duration correlates with outcome quality. Deals that close within 6 months of process initiation — suggesting a well-prepared asset and efficient execution — generate higher upfront ratios than deals that extend beyond 12 months. Protracted processes signal weakness and erode counterparty urgency.
Advisor-led processes outperform unadvised processes. Companies that engage experienced transaction advisors generate median upfronts 25-35% above self-represented licensors. The advisor's value comes not from access (most licensors can identify potential partners) but from positioning, process management, and negotiation expertise.
The best-in-class process involves 15-25 parties at the teaser stage, 6-10 at the CDA and data package stage, 3-5 at the management presentation stage, and 2-3 at the term sheet stage. This funnel shape creates consistent competitive pressure at every decision point.
Benchmark licensing outcomes by stage and TA on Solidus at calculator.ambrosiaventures.co.
What most companies get wrong
The first mistake is starting the process too late. Companies that initiate out-licensing when they need the capital — when the runway is short and the alternatives are limited — negotiate from weakness. The best processes start 12-18 months before the company needs the proceeds, when the balance sheet provides genuine optionality.
The second mistake is poor positioning. The most common positioning failure is presenting the asset through the licensor's lens rather than the counterparty's. Pharma companies do not buy science; they buy solutions to portfolio problems. An asset positioned as "a novel mechanism with differentiated pharmacology" is less compelling than one positioned as "the next-generation franchise replacement for your $4B product facing biosimilar competition in 2028."
The third mistake is losing process control. Once a counterparty gains bilateral access — private meetings, direct data requests, timeline concessions — the competitive dynamic collapses. Every interaction should reinforce that other parties are engaged and progressing at a similar pace.
The fourth mistake is anchoring on the wrong comparables. Licensors who point to the largest deal in their therapeutic area as a comp are setting expectations they cannot meet. Counterparties anchor on median outcomes, not outliers. The right comp set is narrower and more specific: same stage, same TA, same modality, and ideally the same counterparty's prior transactions.
Related Insights
Further reading from our research.
Bring us your transaction.
We’ll meet you at peer level — anywhere in the world.